Literature DB >> 14522248

Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma.

Andrew B Gladden1, J Alan Diehl.   

Abstract

G1 is the phase of the cell cycle wherein the cell is responsive to growth factor-dependent signals. As such, G1 regulation is frequently disrupted in cancer through deregulation of cyclin/CDK activity; deregulation of G1 phase provides tumorigenic cells with a growth advantage. Cyclin E, the regulatory cyclin for CDK2, is considered a requisite regulator of G1 progression. Cyclin E is overexpressed in cancer, suggesting that cyclin E/CDK2 deregulation contributes to tumorigenesis. Two papers now challenge both the concept that cyclin E/CDK2 is a requisite component of the cell cycle machine and efforts to develop cyclin E/CDK2 inhibitors as antiproliferative therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522248     DOI: 10.1016/s1535-6108(03)00217-4

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  24 in total

1.  Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

2.  Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines.

Authors:  Timothy C Horan; Michael A Zompa; Christopher T Seto; Kyu Kwang Kim; Richard G Moore; Thilo S Lange
Journal:  Invest New Drugs       Date:  2011-08-02       Impact factor: 3.850

3.  Topochemical models for prediction of cyclin-dependent kinase 2 inhibitory activity of indole-2-ones.

Authors:  Harish Dureja; Anil Kumar Madan
Journal:  J Mol Model       Date:  2005-06-02       Impact factor: 1.810

4.  Hepatitis C Virus core+1/ARF Protein Modulates the Cyclin D1/pRb Pathway and Promotes Carcinogenesis.

Authors:  Savvina Moustafa; Ioannis Karakasiliotis; Penelope Mavromara
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

5.  Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27(Kip1)-dependent G1/S cell cycle arrest in conjunction with NF-kappaB activation.

Authors:  Christina Batsi; Soultana Markopoulou; Evangelos Kontargiris; Christiana Charalambous; Christoforos Thomas; Savvas Christoforidis; Panagiotis Kanavaros; Andreas I Constantinou; Kenneth B Marcu; Evangelos Kolettas
Journal:  Biochem Pharmacol       Date:  2009-03-27       Impact factor: 5.858

6.  A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells.

Authors:  Rakesh K Singh; Thilo S Lange; Kyu Kwang Kim; Laurent Brard
Journal:  Invest New Drugs       Date:  2009-10-29       Impact factor: 3.850

7.  Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines.

Authors:  Rakesh K Singh; Thilo S Lange; Kyukwang Kim; Yongping Zou; Casey Lieb; Giselle L Sholler; Laurent Brard
Journal:  Bioorg Med Chem Lett       Date:  2007-08-19       Impact factor: 2.823

8.  Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.

Authors:  Anders Ström; Johan Hartman; James S Foster; Silke Kietz; Jay Wimalasena; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

9.  Activated Src abrogates the Myc requirement for the G0/G1 transition but not for the G1/S transition.

Authors:  Tulsiram Prathapam; Sarah Tegen; Thordur Oskarsson; Andreas Trumpp; G Steven Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

10.  Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model.

Authors:  Thilo S Lange; Carolyn McCourt; Rakesh K Singh; Kyu Kwang Kim; Ajay P Singh; Brian S Luisi; Onur Alptürk; Robert M Strongin; Laurent Brard
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.